Medical Condition News

RSS

Bolus intracoronary abciximab reduces infarct size in high-risk patients with STEMI

Administration of a bolus dose of the anticoagulant drug abciximab into the coronary artery involved in causing a certain type of heart attack among patients who were undergoing a percutaneous coronary intervention and also receiving another anticoagulant resulted in reduction in the size of damage to the heart muscle at 30 days, while a procedure that involved use of a catheter to remove the blood clot blocking that coronary artery did not produce these results, according to a study appearing in JAMA.

27 Mar 2012

FDA issues Complete Response letter to MAP's NDA for LEVADEX

MAP Pharmaceuticals, Inc. today announced that the United States Food and Drug Administration (FDA) has issued a Complete Response letter to its New Drug Application (NDA) for LEVADEX (dihydroergotamine) inhalation aerosol.

27 Mar 2012

Study finds imbalance between growth of PCI centers and the U.S. population

There is an imbalance between the rapid growth of cardiac catheterization laboratories, which provide percutaneous coronary intervention (PCI) procedures, relative to the growth in the overall U.S. population, as well as patients who experience an acute heart attack, or ST-elevation myocardial infarction (STEMI), according to a study presented March 25 at the 61st annual American College of Cardiology (ACC) scientific session.

27 Mar 2012

Medtronic Resolute DES found effective through two years

According to new clinical data presented today at ACC.12 -- the 61st Annual Scientific Session & Expo of the American College of Cardiology (ACC) -- the Resolute drug-eluting stent (DES) from Medtronic, Inc. maintains a powerful and persistent treatment effect for a wide variety of patients with coronary artery disease, including those with diabetes mellitus, through two years of follow-up.

From Medtronic 27 Mar 2012

Mayo Clinic researchers join expedition to Everest

It's a natural laboratory for studying heart disease, lung problems, muscle loss, sleeping disorders and new medical technologies. It's also the highest mountain in the world. Mount Everest's extreme altitude puts climbers under the same conditions experienced by patients suffering from heart disease, obesity or advanced age. To take advantage of that, Mayo Clinic researchers are joining an expedition to Everest with National Geographic, The North Face and Montana State University.

26 Mar 2012

NIH OBSSR creates Web-based interactive anthology

A Web-based interactive anthology will provide psychologists, economists, anthropologists, sociologists and other scientists with the latest research methods and tools to address emerging challenges in public health, such as the obesity epidemic and the rise of chronic diseases such as heart disease.

26 Mar 2012

Lower BMI increases risk during insertion of ICDs

Patients who are underweight or small in stature are twice as likely to experience complications or die during insertion of an implantable cardioverter-defibrillator (ICD) compared to obese and normal-weight patients, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.

26 Mar 2012

EMA accepts Arena's lorcaserin MAA for weight control

Arena Pharmaceuticals, Inc. announced today that the European Medicines Agency (EMA) has accepted the filing of a Marketing Authorization Application (MAA) for lorcaserin, an investigational drug candidate intended for weight control, including weight loss and maintenance of weight loss, in patients who are obese (BMI >30) or patients who are overweight (BMI >27) and have at least one weight-related co-morbid condition.

26 Mar 2012

CardioFocus introduces HeartLight Endoscopic Ablation System for AF in the Netherlands

CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), announces its technology is now available in the Netherlands. Physicians at Isala Klinieken in Zwolle were the first in the country to incorporate visually guided ablation into their regular therapeutic practice and have successfully treated several patients.

26 Mar 2012

CSL Behring commences enrollment in SCIg PATH trial for CIDP

CSL Behring has announced that the first patient has been enrolled in the PATH study, an international clinical trial designed to evaluate the efficacy, safety, and tolerability of two different doses of subcutaneous immunoglobulin (SCIg), compared with placebo, in maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).

26 Mar 2012

Minimally invasive treatments could target ‘hunger hormone’

A minimally invasive treatment may target hunger at its source, another uses X-ray visible embolic beads to block arteries to the stomach and suppress hunger and a third explores the use of stem cells to repair vertebral disc degeneration. Initial results from all these studies were reported at the Society of Interventional Radiology's 37th Annual Scientific Meeting in San Francisco, Calif.

26 Mar 2012

Raisins may help lower blood pressure

If you have slightly higher than normal blood pressure - known as prehypertension - consider eating a handful of raisins. New data suggest that, among individuals with mild increases in blood pressure, the routine consumption of raisins (three times a day) may significantly lower blood pressure, especially when compared to eating other common snacks, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.

26 Mar 2012

FDA approves Teva's QNASL nasal aerosol corticosteroid

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has approved QNASL Nasal Aerosol, a new, "dry" nasal aerosol corticosteroid that treats seasonal nasal and year-round nasal allergy symptoms in adults and adolescents 12 years of age and older.

26 Mar 2012

Early growth predicts strength of the hip bone in childhood

Researchers from the MRC Lifecourse Epidemiology Unit, University of Southampton, have presented evidence that early growth predicts the size, mineralisation, shape and strength of the hip bone in childhood.

26 Mar 2012

Study reveals mechanism by which AD may cause memory loss

Alzheimer's disease (AD) steals memory and ruins lives. Despite near-daily reports of promising new therapies, AD remains unchecked. Now a new study reveals the mechanism by which AD may cause memory loss, suggesting new therapies.

26 Mar 2012

Stem cells from own bone marrow improve heart function

A research network led by a Mayo Clinic physician found that stem cells derived from heart failure patients' own bone marrow and injected into their hearts improved the function of the left ventricle, the heart's pumping chamber. Researchers also found that certain types of the stem cells were associated with the largest improvement and warrant further study.

26 Mar 2012

CCTA identifies more patients with coronary artery disease

Coronary CT angiography (CCTA) scans allow doctors to determine safely and more quickly which patients at low-to intermediate-risk for a heart attack can be discharged from hospital emergency departments (EDs) than traditional methods, according to the results of a large, multicenter American College of Radiology Imaging Network (ACRIN) trial published online today in the New England Journal of Medicine.

26 Mar 2012

Theracurmin shows positive impact on human diastolic functions

The research group led by Dr. Koji Hasegawa, Director of the Translational Research Division at the National Hospital Organization Kyoto Medical Center and Dr. Tatsuya Morimoto, Professor at the Molecular Medicine School of Pharmaceutical Sciences, University of Shizuoka, announced today based on the recent human clinical trials, that Theracurmin has continuously shown positive impact on human diastolic functions.

26 Mar 2012

Population-wide community and clinical prevention program reduces cardiovascular risk profile

A population-wide community and clinical prevention program involving 10,000 adults meaningfully reduced the cardiovascular (CV) risk profile among a substantial portion of the population as indicated by those participating in screenings. Findings also indicate the level of improvements differ by gender for specific cardiovascular risk factors.

26 Mar 2012

Promising results from Esperion ETC-1002 Phase 2 clinical trial for dyslipidemia

Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced positive results from a Phase 2 clinical trial for ETC-1002.

26 Mar 2012